Most human acute myeloid leukaemia (AML) cells have limited proliferative capacity, suggesting that the leukaemic clone may be maintained by a rare population of stem cells. This putative leukaemic stem cell has not been characterized because the available in vitro assays can only detect progenitors with limited proliferative and replating potential. We have now identified an AML-initiating cell by transplantation into severe combined immune-deficient (SCID) mice. These cells homed to the bone marrow and proliferated extensively in response to in vivo cytokine treatment, resulting in a pattern of dissemination and leukaemic cell morphology similar to that seen in the original patients. Limiting dilution analysis showed that the frequency of these leukaemia-initiating cells in the peripheral blood of AML patients was one engraftment unit in 250,000 cells. We fractionated AML cells on the basis of cell-surface-marker expression and found that the leukaemia-initiating cells that could engraft SCID mice to produce large numbers of colony-forming progenitors were CD34+ CD38-; however, the CD34+ CD38+ and CD34- fractions contained no cells with these properties. This in vivo model replicates many aspects of human AML and defines a ne...Continue Reading
Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group
Transplantation of normal and leukemic human bone marrow into immune-deficient mice: development of animal models for human hematopoiesis
Growth of normal versus leukemic bone marrow cells in long term culture from acute lymphoblastic and myeloblastic leukemias
Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia
Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia
Structure, organization, and sequence of alpha satellite DNA from human chromosome 17: evidence for evolution by unequal crossing-over and an ancestral pentamer repeat shared with the human X chromosome.
Long-term marrow culture of cells from patients with acute myelogenous leukemia. Selection in favor of normal phenotypes in some but not all cases
Integrated chromosome 19 transcriptomic and proteomic data sets derived from glioma cancer stem-cell lines
Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases
Isolation and identification of cancer stem cells from a side population of a human hepatoblastoma cell line, HuH-6 clone-5
Induction of tumor stem cell differentiation--novel strategy to overcome therapy resistance in gastric cancer
Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer
Cancer stem/progenitor cell active compound 8-quinolinol in combination with paclitaxel achieves an improved cure of breast cancer in the mouse model
T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumors
Flow cytometry analysis of neural differentiation markers expression in human glioblastomas may predict their response to chemotherapy
The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies
CXCR4 positive cells from Lewis lung carcinoma cell line have cancer metastatic stem cell characteristics
Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.
AML: Role of LSD1 by CRISPR (Keystone)
Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.